Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Kinase Inhibition in Relapsed/Refractory Acute Leukemias
NCT01620216Phase 2Terminated
- Sponsor
- OHSU Knight Cancer Institute
- Start
- May 2012
- Primary completion
- Apr 2017
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label trial of dasatinib, sunitinib, sorafenib, ponatinib, pacritinib and 2 more in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) (7 arms), sponsored by OHSU Knight Cancer Institute. Primary endpoint: Clinical Activity at 28 days. Started May 2012; status: terminated.
02
Drugs
dasatinibsunitinibsorafenibponatinibpacritinib
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT01620216.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01620216.